SI-BONE (SIBN) Corporate presentation summary

Financial performance and growth

• Achieved 11.2% worldwide revenue growth to $52.6 million in Q1 2026, with U.S. revenue up 10% to $49.3 million and 17.3% growth in U.S. active physicians.

• Gross margin reached 79.8% and adjusted EBITDA improved to $2.5 million, a ~440% increase year-over-year.

• Free cash flow improved by approximately 51%, with $144.7 million in cash and equivalents as of May 2026.

• Updated 2026 worldwide revenue guidance is $230.0–$233.0 million, implying 14–16% growth and ~79% gross margin.

• Five years of double-digit U.S. physician base growth and record engagement are driving procedure demand.

Market opportunity and business drivers

• Addressable U.S. market exceeds $3.5 billion, with 470,000 annual target procedures and less than 10% market penetration.

• Three main clinical needs addressed: SI joint dysfunction, pelvic trauma, and spinopelvic fixation.

• Business strategy focuses on innovation, physician engagement, commercial execution, and operational excellence.

• Platform supported by robust clinical data, reimbursement advantages, and scalable infrastructure.

• International expansion underway, including EMEA and Australia.

Product portfolio and innovation

• Portfolio includes iFuse INTRA Ti, iFuse TORQ, iFuse Bedrock Granite, and iFuse TORQ TNT, each targeting specific bone and joint conditions.

• Over 70 issued patents and 48 pending patents protect differentiated technologies.

• Three breakthrough device designations and 185+ peer-reviewed publications support clinical efficacy.

• Recent FDA clearances and CMS reimbursement milestones for new products, including NTAP and TPT payments.

• Products designed for improved osseointegration, surgical efficiency, and expanded indications.